Coronavirus Live Count Map India
remove_red_eye 752 Views
COVID-19 Vaccine Updates
Nusinersen, which has been shown to be effective in the treatment of babies with the rare muscle-wasting disease spinal muscular atrophy type 1 may be effective for muscle control even when treatment is started in children seven months and older, according to a study published online August 29, 2018 in the journal Neurology. Six months after the injection, all 33 participants were alive and continuing treatment. Nusinersen was FDA-approved in December 2016 and is the first and only approved treatment for all types of SMA.